VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX) in a report released on Wednesday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Other equities analysts have also issued research reports about the company. Benchmark reissued a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com assumed coverage on VolitionRx in a report on Wednesday. They issued a “sell” rating on the stock.

VolitionRx Trading Down 3.6 %

VolitionRx stock opened at $0.56 on Wednesday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02. The stock’s fifty day simple moving average is $0.61 and its 200-day simple moving average is $0.65. The firm has a market capitalization of $51.99 million, a P/E ratio of -1.56 and a beta of 1.09.

Hedge Funds Weigh In On VolitionRx

Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares in the last quarter. Millennium Management LLC acquired a new position in VolitionRx in the fourth quarter valued at $36,000. Northern Trust Corp boosted its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. boosted its stake in VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in VolitionRx in the fourth quarter valued at $29,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.